Natalizumab and fingolimod are used as high-efficacy treatments in relapsing-remitting multiple sclerosis. Several observational studies comparing these two drugs have shown variable results, using different methods to control treatment indication bias and manage censoring. The objective of this empirical study was to elucidate the impact of methods of causal inference on the results of comparative effectiveness studies.

Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis / Lefort, M; Sharmin, S; Andersen, J B; Vukusic, S; Casey, R; Debouverie, M; Edan, G; Ciron, J; Ruet, A; De Sèze, J; Maillart, E; Zephir, H; Labauge, P; Defer, G; Lebrun-Frenay, C; Moreau, T; Berger, E; Clavelou, P; Pelletier, J; Stankoff, B; Gout, O; Thouvenot, E; Heinzlef, O; Al-Khedr, A; Bourre, B; Casez, O; Cabre, P; Montcuquet, A; Wahab, A; Camdessanché, J P; Maurousset, A; Ben Nasr, H; Hankiewicz, K; Pottier, C; Maubeuge, N; Dimitri-Boulos, D; Nifle, C; Laplaud, D A; Horakova, D; Havrdova, E K; Alroughani, R; Izquierdo, G; Eichau, S; Ozakbas, S; Patti, F; Onofrj, M; Lugaresi, A; Terzi, M; Grammond, P; Grand'Maison, F; Yamout, B; Prat, A; Girard, M; Duquette, P; Boz, C; Trojano, M; McCombe, P; Slee, M; Lechner-Scott, J; Turkoglu, R; Sola, P; Ferraro, D; Granella, F; Shaygannejad, V; Prevost, J; Maimone, D; Skibina, O; Buzzard, K; Van der Walt, A; Karabudak, R; Van Wijmeersch, B; Csepany, T; Spitaleri, D; Vucic, S; Koch-Henriksen, N; Sellebjerg, F; Soerensen, P S; Hilt Christensen, C C; Rasmussen, P V; Jensen, M B; Frederiksen, J L; Bramow, S; Mathiesen, H K; Schreiber, K I; Butzkueven, H; Magyari, M; Kalincik, T; Leray, E. - In: BMC MEDICAL RESEARCH METHODOLOGY. - ISSN 1471-2288. - ELETTRONICO. - 22:1(2022), pp. 155.1-155.14. [10.1186/s12874-022-01623-8]

Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis

Lugaresi, A
Writing – Review & Editing
;
2022

Abstract

Natalizumab and fingolimod are used as high-efficacy treatments in relapsing-remitting multiple sclerosis. Several observational studies comparing these two drugs have shown variable results, using different methods to control treatment indication bias and manage censoring. The objective of this empirical study was to elucidate the impact of methods of causal inference on the results of comparative effectiveness studies.
2022
Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis / Lefort, M; Sharmin, S; Andersen, J B; Vukusic, S; Casey, R; Debouverie, M; Edan, G; Ciron, J; Ruet, A; De Sèze, J; Maillart, E; Zephir, H; Labauge, P; Defer, G; Lebrun-Frenay, C; Moreau, T; Berger, E; Clavelou, P; Pelletier, J; Stankoff, B; Gout, O; Thouvenot, E; Heinzlef, O; Al-Khedr, A; Bourre, B; Casez, O; Cabre, P; Montcuquet, A; Wahab, A; Camdessanché, J P; Maurousset, A; Ben Nasr, H; Hankiewicz, K; Pottier, C; Maubeuge, N; Dimitri-Boulos, D; Nifle, C; Laplaud, D A; Horakova, D; Havrdova, E K; Alroughani, R; Izquierdo, G; Eichau, S; Ozakbas, S; Patti, F; Onofrj, M; Lugaresi, A; Terzi, M; Grammond, P; Grand'Maison, F; Yamout, B; Prat, A; Girard, M; Duquette, P; Boz, C; Trojano, M; McCombe, P; Slee, M; Lechner-Scott, J; Turkoglu, R; Sola, P; Ferraro, D; Granella, F; Shaygannejad, V; Prevost, J; Maimone, D; Skibina, O; Buzzard, K; Van der Walt, A; Karabudak, R; Van Wijmeersch, B; Csepany, T; Spitaleri, D; Vucic, S; Koch-Henriksen, N; Sellebjerg, F; Soerensen, P S; Hilt Christensen, C C; Rasmussen, P V; Jensen, M B; Frederiksen, J L; Bramow, S; Mathiesen, H K; Schreiber, K I; Butzkueven, H; Magyari, M; Kalincik, T; Leray, E. - In: BMC MEDICAL RESEARCH METHODOLOGY. - ISSN 1471-2288. - ELETTRONICO. - 22:1(2022), pp. 155.1-155.14. [10.1186/s12874-022-01623-8]
Lefort, M; Sharmin, S; Andersen, J B; Vukusic, S; Casey, R; Debouverie, M; Edan, G; Ciron, J; Ruet, A; De Sèze, J; Maillart, E; Zephir, H; Labauge, P; Defer, G; Lebrun-Frenay, C; Moreau, T; Berger, E; Clavelou, P; Pelletier, J; Stankoff, B; Gout, O; Thouvenot, E; Heinzlef, O; Al-Khedr, A; Bourre, B; Casez, O; Cabre, P; Montcuquet, A; Wahab, A; Camdessanché, J P; Maurousset, A; Ben Nasr, H; Hankiewicz, K; Pottier, C; Maubeuge, N; Dimitri-Boulos, D; Nifle, C; Laplaud, D A; Horakova, D; Havrdova, E K; Alroughani, R; Izquierdo, G; Eichau, S; Ozakbas, S; Patti, F; Onofrj, M; Lugaresi, A; Terzi, M; Grammond, P; Grand'Maison, F; Yamout, B; Prat, A; Girard, M; Duquette, P; Boz, C; Trojano, M; McCombe, P; Slee, M; Lechner-Scott, J; Turkoglu, R; Sola, P; Ferraro, D; Granella, F; Shaygannejad, V; Prevost, J; Maimone, D; Skibina, O; Buzzard, K; Van der Walt, A; Karabudak, R; Van Wijmeersch, B; Csepany, T; Spitaleri, D; Vucic, S; Koch-Henriksen, N; Sellebjerg, F; Soerensen, P S; Hilt Christensen, C C; Rasmussen, P V; Jensen, M B; Frederiksen, J L; Bramow, S; Mathiesen, H K; Schreiber, K I; Butzkueven, H; Magyari, M; Kalincik, T; Leray, E
File in questo prodotto:
File Dimensione Formato  
Lefort 2022 -12874_2022_Article_1623.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 1.35 MB
Formato Adobe PDF
1.35 MB Adobe PDF Visualizza/Apri
12874_2022_1623_MOESM1_ESM.docx

accesso aperto

Tipo: File Supplementare
Licenza: Licenza per accesso libero gratuito
Dimensione 30.34 kB
Formato Microsoft Word XML
30.34 kB Microsoft Word XML Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/891269
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
social impact